ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

GSK Wins U.S. Antibiotic Contract

September 24, 2007 | APPEARED IN VOLUME 85, ISSUE 39

GlaxoSmithKline has scored a Department of Defense contract worth up to $41 million over five years to develop a new class of antibiotics. Under the contract, GSK will identify antibacterials targeting gram-negative biothreats as well as conventional gram-negative hospital pathogens, which have become increasingly resistant to current treatments. Gram-negative bacteria, which include Pseudomonas, Klebsiella, and Acinetobacter, are particularly tricky to combat due to an outer membrane that can keep drugs from reaching the bacterial cell. GSK will work on developing drugs that can first penetrate that barrier and then kill the pathogen.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment